GU Cancers 2023 | ADCs for advanced UC and their molecular markers of response

Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, CT, talks on antibody-drug conjugates (ADCs) for advanced urothelial carcinoma and the importance of understanding their associated molecular markers of response. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.